Market Overview

Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For Alkermes plc

Related ALKS
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Alkermes PLC Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Alkermes plc (NASDAQ: ALKS).

In the report, Morgan Stanley noted, “We reduced 2014E EPS from $0.52 to $0.30, near the upper end of management guidance of $0.19–0.32.The main driver was increase in 2014E R&D expenses from $239M to $275M (guidance $260–280M). Boosting out-year R&D spending yielded EPS far below consensus.We cutEPS as follows: '15E from $0.42 to $0.08 in '15E (vs.cons' $0.59), '16E from $0.80 to $0.35 (vs.cons' $1.24), '17E from $1.30 to $0.94 (vs.cons' $1.95),and '18E from $1.76 to $1.41 (vs.cons' $2.79).”

Alkermes plc closed on Wednesday at $42.31.

Latest Ratings for ALKS

DateFirmActionFromTo
Apr 2014Mizuho SecuritiesUpgradesNeutralBuy
Apr 2014Credit SuisseInitiates Coverage onOutperform
Jan 2014Goldman SachsMaintainsNeutral

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ALKS)

Around the Web, We're Loving...

Get Benzinga's Newsletters